Clinical Trials Sponsored by QuatRx Pharmaceuticals Company

Total 532 results

QuatRx Pharmaceuticals Company

Completed

Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are on Oral Glucocorticoid Therapy

Chronic Obstructive Pulmonary Disease | Hypogonadism
QuatRx Pharmaceuticals Company

Completed

Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis

Psoriasis

United States
QuatRx Pharmaceuticals Company
Hormos Medical

Completed

Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors

Erectile Dysfunction | Hypogonadism

United States
QuatRx Pharmaceuticals Company
Hormos Medical

Completed

A Preliminary Clinical Study to Evaluate Fispemifene in the Treatment of Hypogonadism

Hypogonadism

United States
Shionogi
QuatRx Pharmaceuticals

Completed

Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus

Atrophy | Vaginal Diseases
Shionogi
QuatRx Pharmaceuticals

Completed

Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus

Atrophy | Vaginal Diseases
Quark Pharmaceuticals

Completed

QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant (ReGIFT)

Delayed Graft Function

United States, Spain, Canada, Australia, Netherlands, Germany, Belgium, France, Argentina, Brazil, Czechia
Quark Pharmaceuticals

Completed

Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients

Optic Atrophy | Non-arteritic Anterior Ischemic Optic Neuropathy

United States, Israel
Shionogi
Hormos Medical; QuatRx Pharmaceuticals

Completed

Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity

Atrophy | Vaginal Diseases
Quark Pharmaceuticals
Pfizer

Completed

Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study). (MONET)

Age Related Macular Degeneration

Spain, Korea, Republic of, Turkey, Taiwan, United States, Israel, Austria, Philippines, Denmark, Hong Kong, India
Quark Pharmaceuticals

Terminated

QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery

Cardiac Surgery

United States, Germany, Spain, Australia, Austria, Canada, New Zealand, United Kingdom, Belgium, Czechia, France
Quark Pharmaceuticals

Terminated

Evaluation of Renal Function in Subjects Who Had Undergone Cardiac Surgery

Cardiac Surgery

United States
Quark Pharmaceuticals

Terminated

Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Non Arteritic Anterior Ischemic Optic Neuropathy

United States, Australia, Germany, China, India, Italy, Singapore, Israel
Quark Pharmaceuticals

Completed

A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery

Acute Kidney Injury

United States, Canada, Germany
Quark Pharmaceuticals

Completed

Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)

Glaucoma, Angle-closure, Primary, Acute

Singapore, United States, Vietnam
Quark Pharmaceuticals

Completed

PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME) (MATISSE)

Diabetic Retinopathy | Diabetic Macular Edema | Choroidal Neovascularization

United States, Israel, United Kingdom, Belgium, Germany, Poland, Czech Republic
Quark Pharmaceuticals

Completed

I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation

Delayed Graft Function | Other Complication of Kidney Transplant

United States, Spain, Germany, France, Canada
Quark Pharmaceuticals

Completed

A Dose Escalation and Safety Study of I5NP in Patients Undergoing Major Cardiovascular Surgery

Acute Renal Failure | Injury of Kidney

United States, Israel, Switzerland
Quark Pharmaceuticals

Terminated

A Dose Escalation and Safety Study of I5NP to Prevent Acute Kidney Injury (AKI) in Patients at High Risk of AKI Undergoing Major Cardiovascular Surgery (QRK.004)

Acute Kidney Injury | Acute Renal Failure

United States
Shionogi
Hormos Medical; QuatRx Pharmaceuticals

Completed

A Clinical Study to Evaluate the Safety of Ospemifene

Atrophy | Vaginal Diseases
Shionogi
Hormos Medical; QuatRx Pharmaceuticals

Completed

A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women

Atrophy | Vaginal Diseases
Shionogi
Hormos Medical; QuatRx Pharmaceuticals

Completed

A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women

Atrophy | Vaginal Diseases
Quark Pharmaceuticals
Pfizer

Completed

Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD)

Age-Related Macular Degeneration

United States, Israel
Quark Pharmaceuticals
Pfizer

Terminated

Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema (DEGAS)

Diabetes Complications | Diabetic Retinopathy

United States, United Kingdom, Italy, Israel, Germany, Peru, Denmark, India
Tetraphase Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections (IGNITE1)

Complicated Intra-abdominal Infections

United States, France, Ukraine, Argentina, Bulgaria, Romania, South Africa, Germany, Estonia, Russian Federation, Lithuania, Czechia, Latvia
Tetraphase Pharmaceuticals, Inc.

Completed

Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections

Complicated Intra-abdominal Infection

United States, Latvia, Lithuania, Romania, India, Bulgaria
Tetraphase Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections (IGNITE4)

Complicated Appendicitis | Complicated Intra-abdominal Infections

Ukraine, United States, Bulgaria, Romania, Estonia, Russian Federation, Lithuania, Hungary, Latvia, Georgia, Czechia
Tetraphase Pharmaceuticals, Inc.

Completed

A Thorough QT/QTc Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization

Normal Healthy Subjects
Tetraphase Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections

cUTI

United States, Latvia, Poland, Czechia, Romania, Ukraine, Russian Federation, Georgia, Colombia, Bulgaria, Estonia, Greece, Hungary, Israel, Italy, Mexico, Moldova, Republic of, South Africa
Tetraphase Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections (IGNITE3)

Complicated Urinary Tract Infections

Ukraine, United States, Bulgaria, Romania, Estonia, Russian Federation, Hungary, Austria, Slovakia, Latvia, Moldova, Republic of, Georgia
Tetraphase Pharmaceuticals, Inc.

Completed

A Safety and PK Study of IV Eravacycline

Bacterial Infections

United States
Tetraphase Pharmaceuticals, Inc.

Completed

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects

Impaired Hepatic Function

United States
Tetraphase Pharmaceuticals, Inc.

Completed

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With End Stage Renal Disease and Healthy Subjects

End Stage Renal Disease
Whanin Pharmaceutical Company

Enrolling by invitation

Study Evaluating the Efficacy and Safety of WID-RGC20(Cariprazine) in Patients With Schizophrenia

Schizophrenia

Korea, Republic of
Colby Pharmaceutical Company

Completed

Safety, Tolerability and Immunogenicity of Fluzone® With and Without JVRS-100 in Elderly Subjects

Influenza
Whanin Pharmaceutical Company

Completed

Bioequivalence Study in Healthy Subjects by Using of Chlorpromazine HCl 100mg Tablets

Healthy Subject

Korea, Republic of
Darnitsa Pharmaceutical Company

Completed

Efficacy and Safety Study of Ketorolac / Pitofenone / Fenpiverinium for the Treatment of Patients With Pain After Surgical Abdominal and Pelvic Operations

Postsurgical Pain

Ukraine
Whanin Pharmaceutical Company

Completed

Bioequivalence Study in Patients With Schizophrenia by Using Clozaril 100 mg Tablet (Clozapine) and WID-CLZ18

Schizophrenia

Korea, Republic of
Whanin Pharmaceutical Company

Completed

Clinical Trial for Zebinix (Eslicarbazepine Acetate) in Healthy Korean and Caucasian Adult

Partial-onset Seizures With or Without Secondary Generalisation

Korea, Republic of
Whanin Pharmaceutical Company

Completed

Safety and Efficacy of WIN-901X in Asthma

Asthma

Korea, Republic of
Whanin Pharmaceutical Company

Completed

An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia

Alzheimer Type Dementia

Korea, Republic of
Colby Pharmaceutical Company

Completed

Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant (H-100-001)

Influenza

United States
Tetraphase Pharmaceuticals, Inc.
PRA Health Sciences

Completed

Phase 1, Safety and Bronchopulmonary PK Study in Healthy Volunteers (BAL)

Healthy Subjects

United Kingdom
Hanmi Pharmaceutical Company Limited

Not yet recruiting

A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Recruiting

Dose Escalation and Expansion Study of BH3120 in Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

Korea, Republic of, United States
Hanmi Pharmaceutical Company Limited

Recruiting

Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

Korea, Republic of, Australia
Hanmi Pharmaceutical Company Limited

Recruiting

Phase 2 Study to Assess the Safety, PK, and PD in SBS-IF Subjects

Short Bowel Syndrome

Belgium, Korea, Republic of, United States, Germany, Denmark, France, Poland
Hanmi Pharmaceutical Company Limited

Completed

Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP1802 to HGP1705 in Healthy Volunteers

Healthy Volunteer

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP2105 to RLD2104 in Healthy Volunteers

Healthy Volunteer

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension (HM_APOLLO)

Hypertension

Korea, Republic of

Clinical Trials Sponsored by QuatRx Pharmaceuticals Company

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations